Technical Data
Interleukin 10, Recombinant, Human (IL-10, Cytokine Synthesis Inhibitory Factor, CSIF)
Molecular Biology Storage: -20CShipping: RT
Interleukin-10 is produced by murine T-cells following their stimulation by lectins. The main source for B-cell-derived Interleukin-10 in mice are Ly-1 B-cells that express CD5 and CD11. Murine keratinocytes also produce IL10. In humans IL-10 is produced by activated CD8(+) peripheral blood T-cells, by T-helper CD4 (+) T-cell clones (resembling Th0, Th1, and Th2) after both antigen-specific and polyclonal activation, by B-cell lymphomas, and by monocytes following cell activation by bacterial lipopolysaccharides and mast cells. B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of IL-10 into the conditioned medium. The synthesis of IL-10 by monocytes is inhibited by IL-4 and IL-10.

Recombinant Human IL-10 is a single, glycosylated polypeptide chain containing 161 amino acids and having a molecular mass of 18.6kD.

The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Pro-Gly-Gln-Thr.

Biological Activity:
Interleukin-10 is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent co-stimulation with murine IL-4 of MC-9 cells was found to be < 2ng/ml, corresponding to a Specific Activity of 1.5 x 10e7 IU/mg.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
Source: Recombinant, Human (CHO cells)
Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: Less than 0.1ng/ug (IEU/ug) .
Concentration: ~0.1mg/ml
Form: Supplied as a lyophilized powder in 60mM PBS, pH 6.5, 100mM sodium chloride. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to a concentration of 0.1mg/ml, which can then be further diluted to other aqueous solutions.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Prognostic role of Ebstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Ozyar E, Ayhan A, Atahan IL, Cancer Invest 2004;22(4):483-91 2. Accelerated prion disease in the absence of interleukin-10. Thackray AM, McKenzie AN, Lauder A, J Virol 2004 Dec;78(24):13697-707 3. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Chang DM, Chu SJ, Kuo SY, Ann Rheum Dis 2004 Dec;63(12):1623-6 4. Increased ratio of tumor necrosis factor-alpha to interleukin-10 production is associated with Schistosoma haematobium-induced urinary-tract morbidity. Wamachi AN, Mayadev JS, Magak PL, Koech DK, J Infect Dis 2004 Dec 1;190(11):2020-30 5. Maternal infection-induced white matter injury is reduced by treatment with interleukin-10. Rodts-Palenik S, Wyatt-Ashmead J, Thigpen B, Granger J, Am J Obstet Gynecol 2004 Oct;191(4):1387-92 6. Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. Specht S, Volkmann L, Hoerauf A, Infect Immun 2004 Nov;72(11):6287-93.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.